 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
TLGT = Market Cap $70 Million / 69 Drugs on Market in USA & Canada / 22 Drugs awaiting FDA approval / Additional 39 Products in Pipeline / Profitability expected this year / Strong Insider & Institutional Ownership (see below) = Cheapest Pharma play out there with significant upside potential ..Fair value is between $6-8 right NOW .GL Teligent (TLGT) Market Cap: $70 Million Price: $1.31 Shares Out: 53.7 Million We currently have 22 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.6 billion (IQVIA, June 2018). Institutional Ownership: Signet Healthcare Partners LLC 9,851,861 venBio Select Advisor LLC 5,299,431 Elk Creek Partners LLC 4,602,755 BlackRock Fund Advisors 3,257,509 Prosight Management LP 3,240,761 Broadfin Capital LLC 3,052,852 AMI Asset Management Corp. 2,714,292 The Vanguard Group, Inc. 2,165,610 Eversept Partners LP 2,112,098 Sanders Morris Harris LLC (Investment Management) 1,545,032   | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |